BusinessCidara Provides Corporate Update and Reports Third Quarter 2017 Financial ResultsBy Nasdaq OMXNov 8, 2017, 9:01 PM UTC
BusinessPROVECTUS BIOPHARMACEUTICALS RECEIVES SECOND CANCER COMBINATION THERAPY PATENT FROM THE UNITED STATES PATENT AND TRADEMARK OFFICEBy Nasdaq OMXNov 7, 2017, 9:00 PM UTC
BusinessCidara Therapeutics to Report Third Quarter 2017 Financial Results and Provide Corporate UpdateBy Nasdaq OMXNov 1, 2017, 8:05 PM UTC
BusinessFluidigm Introduces Imaging Mass Cytometry System for Highly Multiplexed Protein Detection in TissuesBy Nasdaq OMXOct 24, 2017, 12:01 PM UTC
BusinessPROVECTUS ANNOUNCES RESULTS FROM ELICITATION STUDY OF PATIENT-PERCEIVED IMPACTS FROM STAGE III AND EARLY-STAGE IV MELANOMABy Nasdaq OMXOct 23, 2017, 12:00 PM UTC
BusinessImmune Design Announces G100’s Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin’s LymphomaBy Nasdaq OMXOct 19, 2017, 8:05 PM UTC
BusinessTempus Unveils Tempus xT, 595 Gene Panel Aimed at Empowering Data-Driven Cancer CareBy Nasdaq OMXOct 19, 2017, 2:30 PM UTC
BusinessCidara Therapeutics Announces Pricing of $20 Million Private Placement of Common StockBy Nasdaq OMXOct 19, 2017, 1:01 PM UTC
